Gene Therapy Firm Freeline Successfully Tops Up Series C
CEO Says $120m Financing Will Advance Key Clinical Programs
Executive Summary
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.
You may also be interested in...
Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors
UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.
£88m Series B For Syncona-backed Freeline To Advance Liver Gene Therapy Focus
Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.